Ulcerative colitis (moderate to severely active) - vedolizumab [ID691]: evaluation report and supporting information

Table of contents
(Please note that the report has been organised into three separate sections in order to make file downlods more manageable.)

 

A. Evaluation report part1 (pdf portfolio)

01 - Pre-Meeting Briefing prepared by NICE

02 - Submission from the technology manufacturer - Takeda

 

B. Evaluation report part 2 (pdf file)

03 - NICE request to the manufacturer for clarification on their submission

 

C. Evaluation Report part 3 (pdf portfolio)

04 - Company clarification response

05 - Consultee submission -British Society Gatreoentrology

06 - Consultee submission -British Society Gastreoentrology

07 - Consultee submission -Crohn's and Colitis UK

08. Consultee submission - NHS Thanet CCG's & NHS South Kent Coast

09 - Consultee submission -Royal College of Physicians

10 - Consultee submission - UK Clinical Pharmacy Association (UKCPA)

11 - Patient expert personal perspective - Cleaver

12 - Patient expert personal perspective - Singh

13 - Clinical expert personal perspective - Hawthorn

14 - Evidence Review Group report prepared by Sheffield of Health and Related Research

15 - Evidence Review Group report - erratum

16 - Company factual accuracy check of Evidence Review Group report

 

 

Please be advised that the format of evaluation reports shared on the NICE website has recently changed, for ease of user navigation between individual documents contained in the report.

It is a requirement of the new (PDF portfolio) format that Adobe Reader is used to view the document. Please follow the link at the bottom of this page to download Adobe Reader if required.

If you have any feedback on the new format please contact the Project Manager for this appraisal.

This page was last updated: 26 November 2014